The preprint presents a large, multi-method comparative genomics and experimental validation study of Hok type I toxins: 32,532 loci (44,248 loci reported across datasets), 1,747 unique peptides (1,264 in RefSeq subset), wide sequence diversity (mean pairwise identity 41.5%), enrichment of Hok in prophages and large conjugative plasmids, and experimental toxicity for 30/31 tested homologs β all supported by comprehensive methods and publicized supplementary data
Core source:
The study dramatically expands the catalog of known Hok sequences and shows most representatives are toxic when expressed β solidifying the interpretation that Hok peptides are active membrane-targeting toxins broadly distributed (mainly) within Enterobacteriaceae and frequently associated with mobile elements such as large conjugative plasmids and prophages, and that RNA structure-aware searches materially increase detection of divergent T1TAs (
Degrees of confidence: the genomic detection and clustering results are well supported by multiple bioinformatic approaches and large sample size (thousands of genomes). The experimental toxicity data (30/31 toxic) are convincing for the tested constructs. Major claims that could be falsified: (a) Hok enrichment in prophages and large plasmids could be overturned if broader prophage detection or inclusion of metagenomes changes the enrichment signal; (b) the assertion that inter-genera HGT is predominantly plasmid-mediated could be weakened if less-stringent but well-supported HGT inferences (synteny and plasmid backbone phylogeny) show more chromosomal transfers.
If expanded metagenomic surveys revealed numerous non-Enterobacteriaceae Hok homologs or showed that Hok prevalence in environmental bacteria is far higher and not enriched on mobile elements, that would change conclusions about distribution and HGT; likewise, failure to reproduce toxicity for many homologs under more physiological expression conditions would challenge the claim that most homologs are functional toxins.
Primary source for all claims in this review:
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.